Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 247

recruiting
3 968
countries
28
conditions
2 103

3 294 trials match your criteria

Cervix carcinoma

Not recruiting

Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan

Pyoderma gangrenosum

Not recruiting

Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone

Asthma+1

Not recruiting

Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Budesonide

Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Metastatic neoplasm

Not recruiting

Study on the Effects of Trastuzumab Deruxtecan in Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.